论文部分内容阅读
经导管主动脉瓣膜置入术(TAVI)是近年来出现的一种治疗重度主动脉瓣狭窄(AS)的新兴技术。对于高龄且合并多脏器功能不全的患者,传统外科手术换瓣治疗风险大,且部分患者存在手术禁忌证,而经导管置换主动脉瓣膜具有微创、无需体外循环及输血、住院时间缩短等优点。国内目前仅有阜外医院及解放军总医院心内科第一批启动了该项目。本文报告了解放军总医院2011年2月对1例重度AS患者行TAVI治疗并随访1个月的结果。
Transcatheter aortic valvuloplasty (TAVI) is a new technology developed in recent years to treat severe aortic stenosis (AS). In elderly patients with multiple organ dysfunction, the risk of traditional surgery for valve replacement is high, and some patients have contraindications to surgery. Transcatheter replacement of the aortic valve with minimal invasiveness, no need for extracorporeal circulation and blood transfusion, shorter hospital stays, etc. advantage. At present, only Fuwai Hospital and People’s Liberation Army General Hospital, the first batch of cardiology started the project. This article reports the results of TAVI treatment and one month follow-up of one PLA with severe AS in February 2011 by PLA General Hospital.